Isoray, Inc. provided sales guidance for the first quarter ending September 30, 2022. In the short term, although the company don't have adequate supply now of Cesium-131, the company expects a decline in sales in the first fiscal quarter of 2023 ending September 30, 2022, versus the prior year. The company currently anticipates total revenue for this period to be between $1.6 million and $1.8 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
11.93 USD | +15.38% | -10.30% | +196.77% |
06-12 | Sector Update: Health Care Stocks Ease Late Afternoon | MT |
06-12 | Sector Update: Health Care Stocks Softer Wednesday Afternoon | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+196.77% | 804M | |
+34.01% | 51.07B | |
+33.84% | 38.86B | |
-8.02% | 38.78B | |
-8.98% | 26.69B | |
+12.56% | 26.35B | |
-19.62% | 19.46B | |
+39.18% | 13.58B | |
+31.47% | 12.46B | |
-3.40% | 11.75B |
- Stock Market
- Equities
- CATX Stock
- News Perspective Therapeutics, Inc.
- Isoray, Inc. Provides Sales Guidance for the First Quarter Ending September 30, 2022